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Abstract
Objective
To assess the effects of dystrophia myotonica protein kinase (DMPK) DNA methylation
(DNAme) epivariation on muscular and respiratory profiles in patients with myotonic dys-
trophy type 1 (DM1).
Methods
Phenotypes were assessed with standardized measures. Pyrosequencing of bisulfite-treated
DNA was used to quantify DNAme levels in blood from 90 patients with DM1 (adult form).
Modal CTG repeat length was assessed using small-pool PCR. The presence of Acil-sensitive
variant repeats was also tested.
Results
DNAme levels upstream of the CTG expansion (exon and intron 11) were correlated with
modal CTG repeat length (rs = −0.224, p = 0.040; rs = −0.317, p = 0.003; and rs = −0.241, p =
0.027), whereas correlations were observed with epivariations downstream of the CTG repeats
(rs = 0.227; p = 0.037). The presence of a variant repeat was associated with higher DNAme
levels at multiple CpG sites (up to 10% higher; p = 0.001). Stepwise multiple linear regression
modeling showed that DNAme contributed significantly and independently to explain phe-
notypic variability in ankle dorsiflexor (3 CpGs: p = 0.001, 0.013, and 0.001), grip (p = 0.089),
and pinch (p = 0.028) strengths and in forced vital capacity (2 CpGs: p = 0.002 and 0.021) and
maximal inspiratory pressure (p = 0.012).
Conclusions
In addition to the CTG repeat length, DMPK epivariations independently explain phenotypic
variability in DM1 and could thus improve prognostic accuracy for patients.
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Myotonic dystrophy type 1 (DM1) is an autosomal dominant
multisystemic1 disorder caused by a CTG repeat expansion in
the 3’untranslated region of the dystrophia myotonica protein
kinase (DMPK) gene.2–4 DM1 affects all systems including
muscular, cardiac, respiratory, endocrine, and CNS. The
hallmark feature of DM1 is the involvement of the muscular
system including presence of myotonia, progressive skeletal
muscle impairment with a distal to proximal pattern, and
respiratory muscle. The phenotypic variability observed in
terms of age at onset, clinical presentation, and severity has led
to a clinical classification that has evolved over time going
from 35 to 5 phenotypes recognized today.6 Although patients
born with a larger expansion usually present a more severe
phenotype than those with a smaller one, the CTG repeat
length only partially explains this large phenotypic variability.
DNA methylation (DNAme) regulates gene expression7 and
alternative splicing8 without modifying the nucleic acid se-
quence of the genes. DNAme occurs mainly on cytosines
upstream of a guanine (CpG dinucleotides). The DMPK
CTG expansion locus harbors a long CpG island, a genomic
structure enriched in CpGs prone to DNAme. This led to
hypothesize that DNAme contributes to disease development
and progression and explains part of the phenotypic variability
reported in DM1.9–16
Only a few studies have been conducted, and all have con-
siderable limitations such as small sample size and inclusion of
multiple DM1 phenotypes, limiting comparison between
studies and the conclusions, which can be drawn. None tested
associations with DM1 clinical phenotypes, except for the
Muscular Impairment Rating Scale (MIRS) in 1 study.12
Therefore, we have assessed DNAme levels at the DMPK
gene locus and tested for association with muscular and re-
spiratory impairments in the largest number of patients with
DM1 with the adult phenotype.
Methods
Standard protocol approvals, registrations,
and patient consents
The study was approved by the Ethics Review Board of the
Centre de sante´ et de services sociaux de Chicoutimi, Canada, and
all participants provided written consent.
Participants
In 2002, 200 of the 416 patients with DM1 followed at the
Neuromuscular Clinic of the Centre de sante´ et des services
sociaux de Jonquie`re (Que´bec, Canada) were randomly se-
lected and recruited in a longitudinal study aimed at identifying
the determinants of social participation. Selection criteria were
(1) age ≥18 years, (2) molecular confirmation of diagnosis
(late-onset vs adult phenotypes), and (3) capacity to provide
informed consent. The adult phenotype was assigned to par-
ticipants who had at least 2 of the following characteristics: (1)
number of CTG repeats >200 in the standard diagnostic test,
(2) Muscular Impairment Rating Score (MIRS) ≥3, and (3)
age at symptom onset <40 years.17 Age at onset was defined as
the age at which the participant presented his first symptom.To
reduce phenotypic variability that is present between patients
with DM1 presenting different phenotypes of the disease, only
90 participants presenting the adult form of the disease were
kept for the analysis. Patients with other forms of muscular
dystrophies including congenital and childhood DM1 were
thus excluded.
Muscle strength measurements
An isometric make test using a MicroFET2 dynamometer
(Hoggan Health Industries, West Jordan, UT) was performed
twice by a trained physiotherapist to measure the strength of
the shoulder abductors, knee extensors, and ankle dorsi-
flexors. The participant’s position was standardized for each
muscle group. If there was more than 10% discrepancy be-
tween 2 assessments for a muscle group, a third measure was
performed, and the mean of the 2 closest values was kept as
the final result. The maximal isometric torque was computed
by multiplying strength units (N) by length of the corre-
sponding lever arm (m).18 A Jamar dynamometer (Asimow
Engineering Co, Sequim, WA) was used to measure grip
strength.19 Three measures were performed with a standard-
ized protocol, and the mean was used as the final result. A B &
L Pinch Gauge (Fabrication Enterprises Inc, New York, NY)
was used to measure lateral pinch strength. Again, 3 measures
were performed with a standardized protocol, and the mean
was used as the final result.19
Respiratory profile assessment
Forced vital capacity, peak expiratory flow, and maximal in-
spiratory and expiratory pressure (cm H2O) were measured by
a respiratory therapist at the Jonquiere Hospital following
a standardized protocol. Percentage of predicted values for
forced vital capacity and peak expiratory flow (% predicted)
were calculated using the equation as in reference 20. Smoking
status was determined using a life habit questionnaire.
DNA extraction and methylation analyses
Blood was collected in EDTA tubes during the same visit
muscular and respiratory profiles were assessed. Buffy coats
were kept at −80°C until DNA extraction using the Gentra
Puregene Blood Kit (Qiagen).
DNA methylation analysis takes advantage of the chemical
propriety of unmethylated cytosines, which are sensitive to
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sodium bisulfite treatment (NaBis; EpiTect Bisulfite Kit,
Qiagen). Treatment of unmethylated cytosines thus generates
a C→T (U) transition, whereas methylated cytosines are
protected from deamination to uracils in the presence of
NaBis, thus remaining cytosines. Combined with NaBis
treatment, pyrosequencing is a quantitative real-time se-
quencing technology that measures the site-specific DNA
methylation percentage for each CpG of a given sequence.
PCR and sequencing primers were designed using Pyromark
Assay Design 2.0 (Qiagen). Primer sequences are provided in
table e-1 (links.lww.com/NXG/A157).
The PyroMark PCR Kit (Qiagen) was used for amplification
of bisulfite-treated DNA. A Pyromark model q24 (Qiagen)
was used to quantify DNA methylation levels.
CTG repeat length analysis and variant
repeat analysis
Small-pool PCR and Southern blot hybridization were used to
measure CTG repeat length. PCR amplification of the DMPK
CTG repeat was performed using the flanking primers DM-C
and DM-DR, as previously described in reference 21. The
PCR buffer was Custom PCR Master Mix-No Taq (Thermo
Scientific #SM 0005) supplemented with 69 mM
2-mercaptoethanol. Taq polymerase (Sigma-Aldrich, United
Kingdom) was used at 1 unit per 10 μL. Where required,
reactions were supplemented with 10% dimethyl sulfoxide
(Sigma-Aldrich), and the annealing temperature reduced from
68°C to 63.5°C. PCR products were digested with Acil (New
England Biolabs UK Ltd) in accordance with the manu-
facturer’s instructions. PCR-amplified DM1 alleles were run on
1% agarose gels in 0.5X tris-borate-EDTA, blotted, and hy-
bridized as described in reference 21. α-32P-dCTP (Perkin
ElmerUK) and the Invitrogen RandomPrimers DNALabeling
System (Thermo Fisher Scientific UK) were used to label the
molecular weight marker (Invitrogen 1 kb+ ladder, Thermo
Fisher Scientific UK) and DNA probes. Flanking primers DM-
C and DM-DR and a patient with DM1 with 56 CTG repeats
were used to amplify the CTG probe. After autoradiography,
blot images were scanned, and then, estimated progenitor allele
length and baseline modal allele lengths were estimated from
the lower boundary21 and the densest part of the expanded
alleles,22 respectively. Allele length was estimated by compari-
son to the 1 kb+ ladder, using CLIQS 1D gel analysis software
(TotalLabs UK). Somatic instability was computed as modal
allele length minus progenitor allele length.
Statistical analyses
Normality of distribution was tested using the Kolmogorov-
Smirnov test and then visually confirmed on histograms. The
following variables were rank transformed to respect the
normality condition of the regression analysis: age, modal and
progenitor CTG repeat length, DNA methylation levels,
smoking, weight, shoulder abductors, knee extensors, ankle
dorsiflexors, grip and pinch strengths, percentage of predicted
forced vital capacity, percentage of predicted peak expiratory
flow, maximal expiratory and inspiratory pressure, age at
symptom onset, and instability. Spearman correlation coef-
ficients were used to assess the association between DNAme
and CTG repeat length. Mann-Whitney U tests were then
applied on residual scores to assess the differences in DNAme
between patients with and without repeat variants. For
Spearman and Mann-Whitney U analysis, linear regression
and resultant unstandardized residuals were used to adjust
DNAme levels for sex and age of the participants. Stepwise
multiple linear regression analyses were applied to identify
variables independently contributing to explain muscular- and
respiratory-related phenotypes. Confounding factors were
added to each model based on their association with the
corresponding phenotype. The 4 CpGs correlated with CTG
repeat length without correction for age and sex were selected
to be included into the stepwise regression model. We used
relaxed 0.1 and 0.15 cutoff p values, respectively, for entry and
Table 1 Characteristics of the sample
Mean ± SD Range
Age 41.0 ± 7.7 20.0–59.0
Sex: women (n, %) n = 55 (61%) NA
Weight (kg) 67.8 ± 16.3 34.9–115.8
Body mass index (BMI) (kg/m2) 25.21 ± 5.61 14.34–43.05
Smoking (pack-years) 7.3 ± 11.0 0–56.0
Muscular Impairment Rating Scale
(MIRS) category (n, %)
2 n = 7 (7.8%) NA
3 n = 22
(24.4%)
NA
4 n = 56
(62.2%)
NA
5 n = 5 (5.6%) NA
Modal CTG repeat length 603.4 ±
267.9
68–1,321
Variant repeats (present n, %) 8 (8.9%) NA
Age at symptom onset 20.4 ± 7.7 10.0–43.0
Shoulder abductors strength (Nm) 40.8 ± 15.7 14.3–94.2
Knee extensors strength (Nm) 80.9 ± 33.1 18.9–165.3
Ankle dorsiflexors (Nm) 14.2 ± 6.7 2.2–35.6
Grip strength (kg) 8.6 ± 6.4 0.0–28.5
Pinch strength (kg) 5.2 ± 1.5 2.2–9.2
Forced vital capacity (% of predicted
value)
82.9 ± 18.7 35.8–130.9
Peak expiratory flow (% of predicted
value)
73.1 ± 16.2 33.4–113.8
Maximal inspiratory pressure (H2O cm) 66.4 ± 23.5 26.0–138.0
Maximal expiratory pressure (H2O cm) 58.5 ± 22.4 23.0–123.0
Abbreviation: NA = not applicable.
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removal of variables within the regression. Significance levels
were set to p < 0.05. Bonferroni correction was applied to
adjust for multiple testing. Statistical analyses were performed
on IBM SPSS statistics version 24 (IBM) software.
Data availability
The data sets generated and/or analyzed during the current
study are not publicly available for ethical reasons, but are
available from the corresponding author on reasonable request.
Results
Description of study participants and overall
DNAme profile within the DMPK locus
The participants are, on average, middle aged and normal
weight, with women being slightly overrepresented. Partic-
ipants were aged 41.0 years (±7.7) and 603.4 repeats (±267.9)
on average (table 1). Eight of the 90 participants were carriers
of a CTG repeat variant (8.9%).
Figure 1 Spearman correlation between DMPK DNA methylation and modal CTG repeat length in patients with myotonic
dystrophy type 1 (DM1)
Each panel (A to E) represents a different CpG. Results corrected for age and sex.
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DNAme levels were quantified at 8 different loci (L1 to L8)
within the CpG island covering 35 and 17 CpG sites upstream
and downstream of the CTG expansion, respectively (figure
e-1, links.lww.com/NXG/A154). Some of these CpGs/loci
have previously been studied in patients with DM1 or in
mousemodels.9–16 Upstream of the CTG expansion, DNAme
profiles are multidimensional with those proximal to the CTG
expansion (L3, 4, and 5 in intron 14 and exon 15) being
unmethylated (<5%) and those more distally located showing
increasing levels of DNAme from ;50% methylation, at L2
(intron 13) to close to fully methylated CpGs at site L1 (exon
11). Downstream of the CTG expansion, the CpG sites tested
showed low (L6; <10%) to very low (L7 and L8; unmethy-
lated to <5%) levels of DNAme.
Associations betweenDNAme and CTG repeats
Although the coefficients are similar, we observed that DNAme
levels were correlated with the CTG repeat length (figure 1) in
opposite directions depending onwhether they were upstreamor
downstream of the CTG expansion. Briefly, DNAme levels in
exon and intron 11 were correlated with modal CTG repeat
length after correction for age and sex (L1g [rs = −0.224; p =
0.040], L1i [rs = −0.317; p = 0.003] and L1k [rs = −0.241; p =
0.027]), whereas those downstream showed a correlation (L6b
[rs = 0.227; p = 0.037] and L6c [rs = 0.201; p = 0.065]). The
results remain significant with slightly stronger correlation coef-
ficients after excluding patients with variant repeat.
We then assessed the links between DNAme and presence or
absence of a variant repeat within the CTG expansion. We
found that the presence of a variant repeat was associated with
higher DNAme levels only with CpGs just downstream of the
repeat. On average, DNAme levels at any of the 5 CpGs tested
were 3–4 times higher (L6; figure e-2, links.lww.com/NXG/
A155). For example, we observed that the meanDNAme level
at L6c for patients with a variant repeat was 15.5%, whereas it
was 4.7% for patients without Acil-sensitive sequence (p <
0.001), even after correction for modal CTG and progenitor
allele length. Although a nonparametric statistical test was
applied, these associations seem primarily driven by 3 par-
ticipants. We have carefully reviewed their familial, metabolic,
and genetic characteristics, and the 2 patients with the highest
levels of DNAme are siblings. No associations were found
between the presence of a variant repeat and DNAme levels
upstream of the CTG expansion.
Stepwise multiple linear regression analyses
We then assessed whether DNAme levels measured at the
DMPK gene locus were associated with muscular strength and
respiratory profile. Using multiple linear regression models and
stepwise procedures, we found that DNAme contributed to
explain variability in muscular and respiratory profiles in-
dependently of theCTG repeat length. These results are shown
in detail in table 2 for tested muscular strength phenotypes and
table 3 for respiratory measures. Very briefly, DNAme levels at
one or more loci contributed significantly to every DM1-
phenotype tested, except for knee and shoulder strengths and
peak expiratory flow. Of interest, robust and persistent asso-
ciations were observed between DNAme levels at L6c and all 3
muscular-related phenotypes tested, whereas our results sug-
gest a similar pattern of associations between DNAme levels
measured at L6b and all respiratory-related phenotypes.
Table 2 Multiple linear regression analysis of muscle impairments of patients with DM1
Shoulder Knee Ankle Grip Pinch
Age NR β = −0.223
p = 0.022
NR NR β = −0.173
p = 0.071
Sex β = 0.703
p < 0.001
β = 0.482 p < 0.001 NR NR β = 0.339
p = 0.001
Modal CTG repeat length β = −0.146
p = 0.066
NR β = −0.442
p < 0.001
β = −0.476
p < 0.001
β = −0.387
p < 0.001
DNA methylation L6b NR NR NR NR NR
DNA methylation L6c NR NR β = 0.340
p = 0.001
β = 0.173
p = 0.089
β = 0.219
p = 0.028
DNA methylation L1i NR NR β = -0.363
p = 0.013
NR NR
DNA methylation L1k NR NR β = 0.467
p = 0.001
NR NR
Variant repeat (presence/absence) NR β = −0.225
p = 0.021
NR NR NR
R2 of the model (p value) 0.529 (<0.001) 0.336 (<0.001) 0.323 (<0.001) 0.222 (<0.001) 0.305 (<0.001)
p Value, Bonferroni corrected <0.001 <0.001 0.001 0.002 <0.001
Abbreviations: ankle = ankle dorsiflexor strength; DM1 =myotonic dystrophy type 1; grip = grip strength; knee = knee extensors strength; NR = variables not
retained in the model in the final model; pinch = pinch strength; shoulder = shoulder abductors strength.
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DNAme levels were also tested for associations with somatic
instability of the CTG repeat and age at symptom onset. We
found that DNAme levels were associated with variability in
somatic instability (differences between progenitor and av-
erage repeat length) of the CTG repeat, but not with age at
symptom onset (table 4). All models except that for peak
expiratory flow remain significant after Bonferroni correction.
In addition to DNAme levels at other loci, age, sex, and
smoking status contributed to explain one or more of the
phenotypes tested.
Discussion
Although epigenetics (DNAme) has been a mechanism of
interest in DM1 since 1993, only 7 studies have been pub-
lished so far. Of them, 5 focused on the DM1 congenital
phenotype.9,11,13–15 Two other studies reported DNAme
analyses related to DMPK and SIX5 gene expression,10,16 and
only one tested association between a clinical phenotype,
namely theMIRS.12 We are the first to study and demonstrate
that DNAme at the DMPK gene locus contributes to vari-
ability of both muscular strengths and respiratory profiles.
Our results also support that DNAme contributes to DM1
phenotypic variability independently of the CTG repeat length.
Our study has been conducted exclusively in 90 patients with
the adult form of the disease, which we believe reduces the
confounding effects of extreme phenotypic and age at sampling
variability that characterizes broader DM1 cohorts and allows
us to reveal new insights into the role of DNAme in DM1.
Figure e-3 (links.lww.com/NXG/A156) summarizes the
results published so far. Our results for sites L1 and L2 are in
line with some studies15,16 showing constitutive DNAme in
intron 11, but not with 1 study,13 although we report differ-
ences in DNAme levels between individuals at these CpG
sites. Our results are also in agreement with those previously
published13,15,16 showing that the L3 region is unmethylated,
although they found some DNAme when patients with DM1
had more than 300 CTG repeats.13,15,16 For the L4 and L5
regions, hypomethylation of the region has been observed in
other studies,9,12–15 although 1 study12 found DNAme at
various degrees in patients with pure CTG repeats, as did an-
other.11 For L6, the region has been found to present some
variability in our study and in mouse,10,11 in patients with variant
repeats,12 and patients with DM1.9 This region has been asso-
ciated with hypomethylation in patients with DM111,13,15 and
patients with DM1with a pure CTG tract.12 The L7 and L8 sites
have been found to be hypomethylated both by our group and in
a previous study.13 The studies published so far are of small to
very small sample size. Also, inconsistencies between the studies
might be explained by the different DNAme quantification
Table 3 Multiple linear regression analysis of respiratory impairments of patients with DM1
FVC PEF MIP MEP
Age NA NA β = −0.332
p = 0.008
NR
Sex NA NA NR β = 0.417
p < 0.001
Modal CTG repeat length β = −0.283
p = 0.012
NR NR NR
DNA methylation L6b β = 0.368
p = 0.002
β = −0.236
p = 0.039
β = 0.266
p = 0.083
β = −0.211
p = 0.067
DNA methylation L6c NR NR β = −0.399
p = 0.012
NR
DNA methylation L1i NR NR NR NR
DNA methylation L1k β = 0.249
p = 0.021
NR NR NR
Variant repeat (presence/absence) NR NR NR NR
Smoking (pack-years) NR β = −0.228
p = 0.046
NR NR
Weight β = −0.266
p = 0.013
NR NR NR
R2 of the model (p value) 0.283 (<0.001) 0.107 (0.018) 0.167 (0.012) 0.219 (0.001)
p Value, Bonferroni corrected <0.001 0.072 0.048 0.004
Abbreviations: DM1 = myotonic dystrophy type 1; FVC = percentage of predicted forced vital capacity; MEP = maximal expiratory pressure; MIP =maximal
inspiratory pressure; NA = variables not considered in themodel based on their lack of associationwith the phenotype; NR = variables not retained in the final
model; PEF = percentage of predicted peak expiratory flow.
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methods, which are in some cases far from ideal. For example,
methylation-sensitive restriction enzymes have been routinely
used, but do not allow detection of small changes in DNAme
unlike pyrosequencing. These studies have also analyzed
a broader range of DM1 phenotypes than in our study. The
other DM1 phenotypes should thus be also investigated.
Of interest, we also report that the CTG repeat length was cor-
related with DNAme, but in opposite directions depending on
which side of the CTG expansion DNAme levels were assessed.
We report a correlation with DNAme measured in intron 11.
Some groups reported similar associations for DNAmemeasured
in closer vicinity of the CTG expansion,9,10,12,15,16 although dis-
crepancies exist.11,14 Overall, ours and previous results support
the hypothesis that DNAme and modal CTG repeat length are
correlated with each other. However, we cannot yet conclude
which of the 2 influences the other.
Of interest, we also found that presence of a variant repeat within
the CTG expansion was associated with higher DNAme levels
downstream of the CTG repeat (L6). Similar results have been
reported showing an association driven by participants who had
more “CG” sequences in their repeat.12 The “CG” content has
not been assessed in our study, precluding us from drawing
a clear conclusion. However, we found that 2 of the 3 patients
with higher DNAme levels were siblings. Variant repeats were
first observed in a small number of families,24,25 suggesting that
they might be inherited. As such, the pattern of each variant
repeat is also probably inherited and similar within families.
Next, we tested whether DNAme was also associated with key
impairments in DM1. DNAme at 2 different CpG sites, both
within the same L6 region downstream of the CTG expan-
sion, contributed independently of the CTG repeat length to
variability of muscular- (L6c; ankle dorsiflexors, handgrip, and
pinch strength) and respiratory-related phenotypes (L6b;
forced vital capacity, maximal inspiratory pressure, and max-
imal expiratory pressure). This suggests that DNAme at those
CpG sites might affect distinctive muscle groups by changing
affinity for different transcription factors. However, no spe-
cific transcription factor consensus sequences covering each
of the CpG sites were found in the ENCODE database. Also,
we did not find that DNAme contributes to strength vari-
ability of proximal muscle groups (shoulder abductors and
knee extensors), which could be explained by several reasons
including measurement errors, muscle impairment level, and
other factors.
At least 3 hypotheses could explain how DNAme might drive
clinical variability in DM1. First, DNAmemight block CTCFs
binding to one or both of the CTCF consensus sequences
located on each side of the CTG expansion, leading to CTCF
insulator disruption ability between DMPK and SIX5.26 Sec-
ond, DNAme might reduce the mRNA levels of DMPK and
SIX5 and thus reducing the number of DMPK and SIX5
protein.10,16 Third, DNAme might alter CTG repeat in-
stability 27,28 through disruption of CTCF binding,28 although
another study reported that it was DNA demethylation that
was promoting repeat instability27 with another one showing
Table 4 Multiple linear regression analysis of phenotypic variability of age at onset of patients with DM1 and somatic
instability of their repeats
Age at onset Somatic instability
Modal CTG Progenitor CTG Modal CTG Progenitor CTG
Age NA NA NR NR
Sex NR NR β = −0.079
p = 0.054
β = −0.137
p = 0.078
Modal CTG repeat length β = −0.380
p = 0.001
NA β = 0.978
p < 0.001
NA
Progenitor allele length NA β = −0.339
p = 0.003
NA β = 0.811
p = <0.001
DNA methylation L6b NR NR β = −0.202
p = <0.001
β = −0.254
p = 0.005
DNA methylation L6c NR NR NR NR
DNA methylation L1i NR NR NR NR
DNA methylation L1k NR NR NR NR
Variant repeat (presence/absence) NR NR NR NR
R2 of the model (p Value) 0.144 (0.001) 0.115 (0.003) 0.870 (<0.001) 0.533 (<0.001)
p Value, Bonferroni corrected 0.002 0.006 <0.001 <0.001
Abbreviations: age at onset = age at symptom onset; DM1 = myotonic dystrophy type 1; NA = variables not considered in the model based on their lack of
association with the phenotype; NR = variables not retained in the final model; somatic instability = somatic instability of the repeat.
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no link between DNAme and CTG repeat instability.14 Of
interest, we found that increased DNAme was associated with
lower somatic instability. Over time, this might be beneficial
for the patients, as longer repeats usually means a worse
prognosis.
Strengths and limitations
Our study is the largest in terms of number of patients with
DM1 with the same phenotype (adult form) and the second
largest overall. Our participants were extensively phenotyped
and genotyped, including measures of CTG repeat length and
occurrence of CTG variant repeats. DNAme was measured in
blood only (this could also be seen as a limitation) and using
pyrosequencing, the gold standard method to assess CpG-
specific DNAme levels, thus reducing potential technical vari-
ability. One limitation is that we only covered a small part of the
DM1 locus (<3%), leaving many other CpG sites to be tested.
Another limitation is that we did not have access to non-DM1
participants, and thus, comparisons with what could be con-
sidered a normal DNAme profile were not possible. However,
the DMPK region has previously been found to be hypo-
methylated near the CTG repeat and hypermethylated in the
region of exons 11 and 12 in controls and the general population
in various studies.9,11,12,29 No new data on the methylation
status of the DMPK region are available on the epigenome
roadmap than the data already published.29
DNAme at the DMPK gene locus contributes to specific
clinical phenotypes (muscular strengths and respiratory
profiles) in DM1. These associations are independent of the
CTG repeat length. Our results thus provide evidence that
measuring DNAme might help to predict progression of the
disease and to establish a more reliable prognosis for those
patients. We nevertheless agree that further studies, in-
cluding longitudinal studies and in other DM1 forms, are
needed before strong conclusions can be drawn and clini-
cally applied.
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